Cargando…

CDK5 inhibition in vitro and in vivo induces cell death in myeloma and overcomes the obstacle of bortezomib resistance

The emergence of new drugs is a major feature of the treatment history of multiple myeloma (MM), which also reflects the current incurability of MM. As a unique member of cyclin dependent kinase (CDK) family, CDK5 participates in numerous tumorigenic or non-tumorigenic processes. The aim of this stu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tang, Hailong, Xu, Li, Cen, Xi, Yang, Li, Feng, Juan, Li, Guang, Zhu, Huafeng, Gao, Shan, Yu, Yan, Zhao, Yaping, Tian, Zhiqiang, Hou, Liping, Yu, Shuchun, Gao, Guangxun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2020
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7169959/ https://www.ncbi.nlm.nih.gov/pubmed/32236619 http://dx.doi.org/10.3892/ijmm.2020.4553

Ejemplares similares

Nelfinavir augments proteasome inhibition by bortezomib in myeloma cells and overcomes bortezomib and carfilzomib resistance
por: Kraus, M, et al.
Publicado: (2013)

HDAC6-Selective Inhibitor Overcomes Bortezomib Resistance in Multiple Myeloma
por: Lee, Sang Wu, et al.
Publicado: (2021)

Monoclonal Antibodies versus Histone Deacetylase Inhibitors in Combination with Bortezomib or Lenalidomide plus Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma: An Indirect-Comparison Meta-Analysis of Randomized Controlled Trials
por: Zheng, Yanhua, et al.
Publicado: (2018)

Overcoming Obstacles
por: Braile, Domingo M.
Publicado: (2015)

Combination treatment with 2-methoxyestradiol overcomes bortezomib resistance of multiple myeloma cells
por: Song, In-Sung, et al.
Publicado: (2013)

Anti-β(2)-microglobulin monoclonal antibodies overcome bortezomib resistance in multiple myeloma by inhibiting autophagy
por: Zhang, Mingjun, et al.
Publicado: (2015)

Inhibition of thioredoxin activates mitophagy and overcomes adaptive bortezomib resistance in multiple myeloma
por: Zheng, Zhihong, et al.
Publicado: (2018)

Overcoming Proteasome Inhibitor-Refractory Multiple Myeloma With Elotuzumab, Bortezomib, Nelfinavir, and Dexamethasone
por: Erath, Alexandra, et al.
Publicado: (2020)

Novel myeloma patient-derived xenograft models unveil the potency of anlotinib to overcome bortezomib resistance
por: Yue, Yanhua, et al.
Publicado: (2022)

Synergistic Efficacy of the Demethylation Agent Decitabine in Combination With the Protease Inhibitor Bortezomib for Treating Multiple Myeloma Through the Wnt/β-Catenin Pathway
por: Jin, Yulong, et al.
Publicado: (2019)

Periplocin Overcomes Bortezomib Resistance by Suppressing the Growth and Down-Regulation of Cell Adhesion Molecules in Multiple Myeloma
por: Aziz, Abdul, et al.
Publicado: (2023)

Low dose dinaciclib enhances doxorubicin-induced senescence in myeloma RPMI8226 cells by transformation of the p21 and p16 pathways
por: Tang, Hailong, et al.
Publicado: (2018)

Chromosome 1q21 gain is an adverse prognostic factor for newly diagnosed multiple myeloma patients treated with bortezomib-based regimens
por: Liu, Xiao, et al.
Publicado: (2022)

Inhibition of TLR4 Signaling Affects Mitochondrial Fitness and Overcomes Bortezomib Resistance in Myeloma Plasma Cells
por: Giallongo, Cesarina, et al.
Publicado: (2020)

Bortezomib in the management of multiple myeloma
por: Laubach, Jacob P, et al.
Publicado: (2009)

Overcoming obstacles to repurposing for neurodegenerative disease
por: Shineman, Diana W, et al.
Publicado: (2014)

Overcoming Obstacles to Drug Repositioning in Japan
por: Nishimura, Yuhei, et al.
Publicado: (2017)

Synergistic effects of nelfinavir and bortezomib on proteotoxic death of NSCLC and multiple myeloma cells
por: Kawabata, S, et al.
Publicado: (2012)

Optimization of Tilmicosin-Loaded Nanostructured Lipid Carriers Using Orthogonal Design for Overcoming Oral Administration Obstacle
por: Wen, Jia, et al.
Publicado: (2021)

Oncolytic Viruses for Cancer Therapy: Overcoming the Obstacles
por: Wong, Han Hsi, et al.
Publicado: (2010)

Sperm DNA fragmentation: overcoming standardization obstacles
por: Majzoub, Ahmad, et al.
Publicado: (2017)

Bortezomib (Velcade™) in the Treatment of Multiple Myeloma
por: Field-Smith, Antonia, et al.
Publicado: (2006)

BAFF is involved in macrophage-induced bortezomib resistance in myeloma
por: Chen, Jing, et al.
Publicado: (2017)

Bortezomib action in multiple myeloma: microRNA-mediated synergy (and miR-27a/CDK5 driven sensitivity)?
por: Ballabio, E, et al.
Publicado: (2012)

Nanoparticle-Based Therapeutics to Overcome Obstacles in the Tumor Microenvironment of Hepatocellular Carcinoma
por: Lu, Yuanfei, et al.
Publicado: (2022)

Exosomal mRNAs and lncRNAs involved in multiple myeloma resistance to bortezomib
por: Tang, Ju‐xian, et al.
Publicado: (2021)

Expression of GITR Enhances Multiple Myeloma Cell Sensitivity to Bortezomib
por: Zhao, Yinghao, et al.
Publicado: (2015)

An obstacle to overcome: cerebral toxoplasmosis in patients living with HIV
por: Filipescu, Irina, et al.
Publicado: (2014)

Dietary Patterns, Genes, and Health: Challenges and Obstacles to be Overcome
por: Frazier-Wood, Alexis C.
Publicado: (2014)

Recruitment, Enrollment, and Retention: Creative Techniques to Overcome Obstacles
por: Sefcik, Justine, et al.
Publicado: (2021)

Overcoming Obstacles in Liquid Biopsy Developments for Prostate Cancer
por: Jang, Albert, et al.
Publicado: (2022)

PSMB7 Is a Key Gene Involved in the Development of Multiple Myeloma and Resistance to Bortezomib
por: Wu, Dong, et al.
Publicado: (2021)

TRIM21 enhances bortezomib sensitivity in multiple myeloma by halting prosurvival autophagy
por: Chen, Jing, et al.
Publicado: (2023)

Harnessing Noxa demethylation to overcome Bortezomib resistance in mantle cell lymphoma
por: Leshchenko, Violetta V., et al.
Publicado: (2015)

Clinical outcomes of bortezomib-based therapy in myeloma
por: Djebbari, Faouzi, et al.
Publicado: (2018)

Bortezomib Treatment Modulates Autophagy in Multiple Myeloma
por: Di Lernia, Giuseppe, et al.
Publicado: (2020)

Entinostat-Bortezomib Hybrids against Multiple Myeloma
por: Ferro, Angelica, et al.
Publicado: (2023)

Pharmacogenomics and chemical library screens reveal a novel SCF(SKP2) inhibitor that overcomes Bortezomib resistance in multiple myeloma
por: Malek, E, et al.
Publicado: (2017)

Analysis of the efficacy and safety of bortezomib for treating newly diagnosed multiple myeloma through different administration methods
por: Zhang, Hong-Mei, et al.
Publicado: (2019)

SHP2 Inhibitors Show Anti-Myeloma Activity and Synergize With Bortezomib in the Treatment of Multiple Myeloma
por: Zhou, Pan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_471e2jj75cd5ns9phdsn8tcg6e